A single next-generation sequencing panel covering 116 cancer-related genes matches the traditional multi-platform approach ...

A multi-omics study links the antiviral protein RSAD2 to CXCL1–CXCR1/2 signaling that recruits macrophages and drives ...

Endometrial carcinoma, a cancer of the lining of the uterus, is the most common gynecologic malignancy in developed nations. Over the past decade, its incidence has steadily increased (approximately 1 ...

A phase 3 trial demonstrated progression-free survival improvements with Tecentriq-chemotherapy combination in patients with endometrial carcinoma. The treatment combination of Tecentriq (atezolizumab ...

Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY ...

The U.S. Food and Drug Administration has approved Merck's Keytruda (pembrolizumab) plus chemotherapy as treatment for adult patients with primary advanced or recurrent endometrial carcinoma. This is ...

Postmenopausal vaginal bleeding is reported by 90% of patients with a diagnosis of endometrial cancer. Risk factors for endometrial cancer include obesity, increasing age, type 2 diabetes, use of ...

Data from the phase 3 RUBY trial may support the use of dostarlimab plus chemotherapy as a new standard of care in patients with newly diagnosed primary advanced or recurrent endometrial carcinoma.

A new review article published in Genes & Diseases sheds light on the complex molecular mechanisms through which tumor-infiltrating immune cells regulate endometrial carcinoma (EC). As one of the most ...

The conversation often begins with subtle changes that women might initially dismiss as normal variations in their monthly cycle. Perhaps unusual bleeding between periods, or discharge that seems ...